Crispr Therapeutics AG 10-Q quarterly reports

CRISPR Therapeutics AG filed its Form 10-Q for the quarter ended June 30, 2026, detailing advancements in its gene-editing therapies, including CASGEVY, alongside financial performance and strategic updates.

CRISPR Therapeutics AG reports Q1 2026 results with increased cash reserves, ongoing R&D investment, and progress in gene-editing therapies.

CRISPR Therapeutics reported an increased net loss in Q3 2025, driven by higher collaboration expenses, while highlighting positive Phase 1 data for CTX310 and ongoing commercialization of CASGEVY.

CRISPR Therapeutics AG reported a significantly increased net loss for Q2 2025, driven by higher operating expenses including a substantial acquired R&D charge, despite ongoing clinical progress and commercialization efforts for CASGEVY.

CRISPR Therapeutics reports a net loss for Q1 2025, but highlights progress in clinical trials and commercialization of CASGEVY.

CRISPR Therapeutics reports a net loss of $85.9 million for the third quarter of 2024, while highlighting progress in its gene editing programs and collaborations.

CRISPR Therapeutics reports a net loss of $243 million for the first half of 2024, alongside updates on clinical programs and collaborations.

CRISPR Therapeutics reports a net loss of $116.6 million for the first quarter of 2024, with significant cash reserves and ongoing progress in its gene editing programs.